Breaking News: FDA clears Ampligen to start a clinical trial in Long Covid
A decade after the U.S. Food and Drug Administration (FDA) did not approve Ampligen (rintatolimod) for the treatment of ME/CFS, this antiviral and immuno-modulator drug is getting a rare second chance. […]
Signature Event Summary — Long Covid: Research, Policy and Economic Impact
As part of our efforts via the Solve Long Covid Initiative, we’ve partnered with the Global Interdependence Center on a year-long webinar and conference series exploring the pandemic’s long-term healthcare, […]
AIM ImmunoTech Announces Update on Ampligen Long Covid Development Program
Today, AIM ImmunoTech, an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, provided an update […]
Ampligen: A General Overview and the Plan for ME/CFS & Long Covid
For the second installment in our clinical diagnostics and treatments webinar series, Solve M.E. welcomes two leaders from bio-pharma company AIM ImmunoTech to discuss their plans for clinical studies of […]
